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Coronavirus disease 2019 (COVID-19) is an ongoing global public threat, resulting in more than 10 million 
cumulative cases and more than 500 000 deaths world-
wide as of June 30, 2020 (1). Older age and comorbidi-
ties are major risk factors for morbidity and mortality in 
patients with COVID-19 (2). Prothrombotic coagula-
tion abnormalities and thromboembolism are emerging 
as frequent complications in critically ill patients with 
COVID-19, and these complications may contribute to 
morbidity and mortality (3). In particular, pulmonary 
embolism (PE) accounts for a majority of thromboem-
bolic events in COVID-19 (4), but the association be-
tween PE and deep vein thrombosis (DVT) in patients 
with COVID-19 remains unclear (5). Furthermore, D-
dimer levels are recognized as an independent predictor 
for survival (6) and thromboembolic events in COV-
ID-19 (7), but the diagnostic accuracy of D-dimer tests 
for PE in patients with COVID-19 is unknown.
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Background: The association of pulmonary embolism (PE) with deep vein thrombosis (DVT) in patients with coronavirus disease 
2019 (COVID-19) remains unclear, and the diagnostic accuracy of D-dimer tests for PE is unknown.
Purpose: To conduct meta-analysis of the study-level incidence of PE and DVT and to evaluate the diagnostic accuracy of D-dimer 
tests for PE from multicenter individual patient data.
Materials and Methods: A systematic literature search identified studies evaluating the incidence of PE or DVT in patients with 
COVID-19 from January 1, 2020, to June 15, 2020. These outcomes were pooled using a random-effects model and were further 
evaluated using metaregression analysis. The diagnostic accuracy of D-dimer tests for PE was estimated on the basis of individual 
patient data using the summary receiver operating characteristic curve.
Results: Twenty-seven studies with 3342 patients with COVID-19 were included in the analysis. The pooled incidence rates of 
PE and DVT were 16.5% (95% CI: 11.6, 22.9; I2 = 0.93) and 14.8% (95% CI: 8.5, 24.5; I2 = 0.94), respectively. PE was more 
frequently found in patients who were admitted to the intensive care unit (ICU) (24.7% [95% CI: 18.6, 32.1] vs 10.5% [95% CI: 
5.1, 20.2] in those not admitted to the ICU) and in studies with universal screening using CT pulmonary angiography. DVT was 
present in 42.4% of patients with PE. D-dimer tests had an area under the receiver operating characteristic curve of 0.737 for PE, 
and D-dimer levels of 500 and 1000 mg/L showed high sensitivity (96% and 91%, respectively) but low specificity (10% and 24%, 
respectively).
Conclusion: Pulmonary embolism (PE) and deep vein thrombosis (DVT) occurred in 16.5% and 14.8% of patients with coronavirus 
disease 2019 (COVID-19), respectively, and more than half of patients with PE lacked DVT. The cutoffs of D-dimer levels used to 
exclude PE in preexisting guidelines seem applicable to patients with COVID-19.
© RSNA, 2020
Supplemental material is available for this article.
This copy is for personal use only. To order printed copies, contact reprints@rsna.org
Pulmonary Embolism and Deep Vein Thrombosis in COVID-19
2 radiology.rsna.org  n  Radiology: Volume 00: Number 0— 2020
Data Extraction
The two independent reviewers extracted the data from the 
articles, and any disagreements were resolved by consensus. 
Extracted data included study characteristics; demographic 
characteristics, including age and sex; severity of COVID-19 
infection (critically ill patients or those admitted to the inten-
sive care unit [ICU] vs noncritically ill patients or those admit-
ted to the general ward); use of anticoagulation at the diagnosis 
of PE or DVT; the number of CT pulmonary angiographic 
examinations performed for the diagnosis of PE; and results, 
including the number of patients with PE and DVT, as well as 
the location of PE.
To evaluate the diagnostic accuracy of D-dimer tests for PE, 
we contacted the corresponding authors of the included articles 
for three items (D-dimer levels, whether CT pulmonary angiog-
raphy was performed, and the presence of PE) in the individual 
anonymized patient data that the authors had already collected 
and presented in their study.
Definition of Outcomes
The primary outcome of this meta-analysis was the incidence 
of PE and DVT in patients with COVID-19. DVT events 
were confined to lower-extremity DVT. The secondary out-
comes were the location of PE (the most proximal luminal fill-
ing defect in a patient; central [main or lobar pulmonary artery 
branch] vs peripheral [segmental or subsegmental branch]) (7) 
and the diagnostic accuracy of D-dimer test for the diagnosis 
of PE in patients with COVID-19.
Quality Assessment
The Newcastle-Ottawa Quality Scale for cohort studies was ap-
plied to assess the quality of the included studies (8). The scale 
assigns a maximum of four points for selection (representative-
ness of the exposed cohort, selection of the nonexposed co-
hort, ascertainment of exposure, demonstration that outcome 
of interest was not present at the start of the study), two points 
for comparability (comparability of cohorts on the basis of the 
design or analysis controlled for confounders), and three points 
for exposure or outcome (appropriate assessment of outcome, 
sufficient period, and adequacy of follow-up period). Studies 
were independently reviewed by two reviewers (Y.J.S., S.H.Y.), 
and any discrepancy was resolved through discussion and con-
sensus. A score of six or higher indicated high quality.
Statistical Analysis
Extracted outcomes were pooled by weighted averages using a 
DerSimonian-Laird random‐effects model. We assessed the extent 
of statistical heterogeneity between studies using the Cochran Q 
test and I2 statistics (9,10), and P values less than .1 or I2 statis-
tics greater than 50% were considered to indicate the presence of 
substantial heterogeneity. To investigate the cause of heterogeneity 
between studies, a subgroup analysis of the following study char-
acteristics was performed: study design, the severity of COVID-19 
infection, and the proportion of patients who underwent CT pul-
monary angiography within the study population and use of pro-
phylactic or therapeutic anticoagulation. Meta-regression was per-
formed using a random-effects model to assess the effect of study 
Abbreviations
COVID-19 = coronavirus disease 2019, DVT = deep vein thrombosis, 
ICU = intensive care unit, PE = pulmonary embolism
Summary
Pulmonary embolism (PE) and deep vein thrombosis (DVT) oc-
curred in 16.5% and 14.8% of patients with coronavirus disease 
2019, respectively, and more than half of patients with PE lacked 
DVT.
Key Results
 n The pooled incidence rates of pulmonary embolism (PE) and 
deep vein thrombosis in patients with coronavirus disease 2019 
(COVID-19) were 16.5% and 14.8%, respectively.
 n Greater disease severity (necessitating admittance to the intensive 
care unit or in critically ill patients: odds ratio, 3.5; 95% CI: 
1.9, 6.3; P , .001) and universal screening with CT pulmonary 
angiography (odds ratio, 5.1; 95% CI: 2.3, 11.5; P , .001) were 
significantly associated with a higher incidence of PE.
 n D-dimer levels greater than 500 and greater than 1000 mg/L 
showed high sensitivity (96% and 91%, respectively) but low 
specificity (10% and 24%, respectively) in the diagnosis of PE in 
patients with COVID-19.
Therefore, we conducted a meta-analysis of the study-level 
incidence and characteristics of PE and DVT in patients with 
COVID-19 in the current literature and evaluated the diagnos-
tic accuracy of D-dimer tests for PE from multicenter individual 
patient data.
Materials and Methods
Literature Search and Study Selection
This study followed the Preferred Reporting Items for System-
atic Reviews and Meta-analyses reporting guidelines, and the 
study protocol was registered in the International Prospective 
Register of Systematic Reviews database (registration number: 
CRD42020196777).
On June 15, 2020, we searched MEDLINE, Embase, the 
Cochrane Library, MedRxiv, and BioRxiv SSRN for studies on 
COVID-19 that reported the incidence of PE, venous throm-
boembolism including DVT, or both, and were published in 
English in 2020 (Appendix E1 [online]). The search strategy was 
designed by two experienced investigators in consensus (Y.J.S., 
S.H.Y.; thoracic radiologists with 4 and 8 years of experience 
with meta-analysis, respectively) and was followed by the litera-
ture search. The search was further supplemented by screening 
the bibliographies of the retrieved articles.
First, both reviewers independently screened all the publica-
tions on the basis of their titles and abstracts. The studies that 
satisfied the inclusion criteria were then retrieved for full-text 
assessments. The following inclusion criteria were applied to de-
termine eligibility: study populations consisting of four or more 
patients with polymerase chain reaction–proven COVID-19, 
studies primarily investigating PE or venous thromboembolic 
events in patients with COVID-19 in vivo, and data described 
in sufficient detail to extract outcomes. We excluded studies 
with postmortem evaluations of PE or venous thromboembolic 
events in COVID-19.
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angiography was performed to ascertain the presence of PE in 
the entire study population in seven studies and in only part or 
an unknown proportion of the study population in 15 studies.
With the Newcastle-Ottawa scale, 14 studies (52%) were 
classified as being of high quality, and the other 13 (48%) were 
of low quality. The results of the quality assessment are presented 
in Table E1 (online).
Incidence of PE and DVT in Patients with COVID-19
The pooled incidence rates of overall PE and DVT were 16.5% 
(95% CI: 11.6, 22.9) and 14.8% (95% CI: 8.5, 24.5), respec-
tively (Fig 2). Significant interstudy heterogeneity was observed 
(I2 = 0.93, P , .001 for PE; I2 = 0.94, P , .001 for DVT). In 
13 studies (1896 patients) that investigated the incidence of 
both PE and DVT, the incidence rates were 10.3% (95% CI: 
5.7, 17.8; I2 = 0.93; P , .001) and 12.0% (95% CI: 5.9, 22.7; 
I2 = 0.95; P , .001), respectively. The pooled proportion of 
positive DVT results in patients with PE was 42% among 88 
PE lesions in eight studies (95% CI: 23, 65; I2 = 0.63; P = .008) 
(Fig E1 [online]). Information on PE location was available for 
318 patients in 14 studies (Table E3 [online]): 39.0% (95% 
CI: 30.0, 48.9; I2 = 0.56; P = .005) were central, and 60.4% 
(95% CI: 50.3, 69.7; I2 = 0.58; P = .003) were peripheral.
The incidence rates of PE and DVT according to study 
characteristics are presented in Table 2. Prospective studies re-
ported a higher incidence of PE but a lower incidence of DVT 
than did retrospective studies. Studies with anticoagulation had 
a lower incidence of PE than did those with no or unknown 
characteristics on PE incidence, and the 
cluster robust estimator was used to ac-
count for correlations among multiple 
effect sizes within a study.
To analyze the diagnostic per-
formance of D-dimer tests for PE, 
a summary receiver operating char-
acteristic curve was estimated with a 
multiple-threshold model, a multilevel 
random-effects model that considers 
sensitivity and specificity as functions 
of the thresholds and accounts for het-
erogeneity across studies, and the cor-
relation of sensitivity with specificity 
(11). We used data from patients who 
underwent CT pulmonary angiogra-
phy, as the presence or absence of PE 
could not be certain without CT pul-
monary angiography. The optimal cut-
offs were estimated by maximizing the 
Youden index under varying weights 
for sensitivity.
Statistical analysis was performed 
using software (Comprehensive Meta- 
Analysis, version 3; Biostat and R, 
version 3.6.; R Foundation for Statis-
tical Computing). The potential for 
publication bias was assessed using 




Of the 1646 references identified in the initial database search, 
27 studies with 3342 patients with COVID-19 were in-
cluded in the analysis of the overall incidence of PE and DVT 
(7,13–38) (Fig 1). Thirteen studies (1896 patients) reported 
the incidence of both PE and DVT (13,14,20,22,25,27–
30,32,33,37,38), whereas nine studies (1022 patients) and 
five studies (424 patients) reported the incidence of PE only 
(7,15,19,21,23,24,31,34,36) and DVT only (16–18,26,35), 
respectively.
Study Characteristics and Quality Assessment
The characteristics of the included studies are summarized in 
Table 1. Three of the 27 studies were prospective, and the 
other 24 were retrospective. The study population comprised 
patients not in the ICU in four studies, patients in the ICU (or 
critically ill patients) in 12 studies, and patients with various 
levels of disease severity in 11 studies. In eight of those 11 stud-
ies, data could be separately extracted for patients in the ICU 
(or critically ill patients) and those not in the ICU (or noncriti-
cally ill patients). The use of prophylactic or therapeutic anti-
coagulation was reported in 24 studies, and no or unknown 
use of anticoagulation was described in three studies. Among 
22 studies that reported the incidence of PE, CT pulmonary 
Figure 1: Flowchart of the literature review process. COVID-19 = coronavirus disease 2019, PCR = polymerase 
chain reaction.
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Figure 2: Forest plots show pooled 
incidence rates of (a) pulmonary embolism 
(PE) (n = 22) and (b) deep vein thrombosis 
(DVT) (n = 18) in patients with coronavirus 
disease 2019. The estimated overall inci-
dence rates of PE and DVT were 16.5% 
(95% CI: 11.6, 22.9) and 14.8% (95% CI: 
8.5, 24.5), respectively. Significant inter-
study heterogeneity was seen in all groups. 
CTPA = CT pulmonary angiography, ICU = 
intensive care unit, RE = random effects. (Fig 
2 continues.)
anticoagulation. Studies of pa-
tients admitted to the ICU or 
critically ill patients reported 
higher incidence rates of PE 
and DVT than did those of pa-
tients who were not admitted 
to the ICU or those of patients 
with various levels of disease 
severity (PE: 24.7% [95% CI: 
18.6, 32.1] vs 10.5% [95% 
CI: 5.1, 20.2]; DVT: 21.2% 
[95% CI: 11.1, 36.8] vs 7.4% 
[95% CI: 3.2, 16.2]). Studies 
in which CT pulmonary angi-
ography was performed in all 
patients showed a higher inci-
dence of PE than did those in 
which CT pulmonary angiog-
raphy was performed in only 
some of the patients or in an 
unknown proportion (30.2% 
[95% CI: 21.0, 41.3] vs 11.3% 
[95% CI: 6.7, 18.4]).
In a univariable meta-regres-
sion analysis, study design and 
use of anticoagulation were not 
associated with an increased in-
cidence of PE (P = .25 and P 
= .38, respectively) (Table 3). 
However, greater disease sever-
ity (P = .0016) and a higher pro-
portion of patients undergoing 
CT pulmonary angiography 
(P = .002) were significantly 
associated with the higher in-
cidence of PE. When multiple 
study-level characteristics were 
adjusted, a higher incidence of 
PE was associated with a study 
population of patients admit-
ted to the ICU or who were 
critically ill (odds ratio, 3.5; 
95% CI: 1.9, 6.3; P , .001) 
Pulmonary Embolism and Deep Vein Thrombosis in COVID-19
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Figure 2 (continued): Forest plots show pooled incidence rates of (c, d) both pulmonary embolism (PE) and deep vein 
thrombosis (DVT) (n = 13) in patients with coronavirus disease 2019. In the 13 studies that reported both PE and DVT, the 
incidence rates were 10.3% (95% CI: 5.7, 17.8) and 12.0% (95% CI: 5.9, 22.7), respectively. Significant interstudy hetero-
geneity was seen in all groups. CTPA = CT pulmonary angiography, ICU = intensive care unit, RE = random effects.
and universal CT pulmonary 
angiography screening in the 
study population (odds ratio, 
5.1; 95% CI: 2.3, 11.5; P , 
.001).
Diagnostic Performance of 
D-dimer for PE in Patients with 
COVID-19
In total, 11 studies pro-
vided data regarding D-
dimer levels and the pres-
ence of PE as assessed with 
CT pulmonary angiography 
in their study population 
(567 patients) (7,14,15,19–
22,24,33,36,38). D-dimer 
levels were higher in patients 
with PE (median, 7625 mg/L; 
n = 218) than in those with-
out PE (median, 1750 mg/L; n 
= 349). The summary receiver 
operating characteristic curve 
yielded an area under the re-
ceiver operating characteristic 
curve of 0.737 (Fig 3), sug-
gesting cutoffs of D-dimer 
levels for PE diagnosis under 
varying weights for sensitivity 
and specificity. For example, 
the cutoff was 4453.2 mg/L 
using the same weight for sen-
sitivity and specificity (sensi-
tivity, 62% [95% CI: 49, 73]; 
specificity, 76% [95% CI: 
65, 84]) (Table E4 [online]). 
With cutoff values of 500 
and 1000 mg/L, the sensitiv-
ity of D-dimer tests for PE 
was 96% (95% CI: 93, 97) 
and 91% (95% CI: 86, 94), 
respectively, and its specificity 
was 10% (95% CI: 7, 14) and 
24% (95% CI: 18, 32) (Table 
4). The negative predicted 
value of the D-dimer level was 
estimated as 95% (95% CI: 
89, 100) in patients not in the 
ICU and as 88% (95% CI: 
78, 97) in patients in the ICU 
by using a cutoff value of 500 
mg/L, and it was predicted as 
96% (95% CI: 92, 99) in pa-
tients not in the ICU and as 
89% (95% CI: 83, 94) in pa-
tients admitted to the ICU by 
using a cutoff of 1000 mg/L.
Suh et al
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Table 2: Pooled Incidence of PE and DVT according to Study Characteristics
Parameter Incidence (%) Heterogeneity*
PE
 Overall 16.5 (11.6, 22.9) NA
  Study design
  Retrospective (n = 20) 15.5 (10.4, 22.6) ,.001, 0.93
  Prospective (n = 2) 25.1 (11.1, 47.2) ,.001, 0.93
 Study population†
  Non-ICU or various (n = 12) 10.5 (5.1, 20.2) ,.001, 0.95
  ICU or critically ill patients (n = 18) 24.7 (18.6, 32.1) ,.001, 0.82
 Anticoagulation
  None or unknown (n = 2) 21.0 (15.6, 27.8) 0.43, ,0.001
  Yes (n = 20) 16.0 (10.8, 23.0) ,.001, 0.93
 Proportion of patients undergoing CT pulmonary angiography
  Part of patients or unknown (n = 15) 11.3 (6.7, 18.4) ,.001, 0.92
  All patients (n = 7) 30.2 (21.0, 41.3) ,.001, 0.91
DVT
 Overall 14.8 (8.5, 24.5) NA
  Study design
  Retrospective (n = 15) 18.8 (10.5, 31.5) ,.001, 0.95
  Prospective (n = 3) 3.0 (0.4, 19.5) ,.001, 0.91
 Study population†
  Non-ICU or various (n = 8) 7.4 (3.2, 16.2) ,.001, 0.93
  ICU or critically ill patients (n = 13) 21.2 (11.1, 36.8) ,.001, 0.93
Note.—Numbers in parentheses are 95% CIs. DVT = deep vein thrombosis, ICU = intensive care unit, NA = nonapplicable, PE = pulmonary 
embolism.
* Values indicate the P value for Cochran Q test and I2.
† When applicable, data were separately extracted for patients admitted to the ICU and those who were not from studies of disease of various 
levels of severity and were presented as different subgroups.
Publication Bias
The funnel plots did not show significant publication bias for 
the incidence of PE and DVT (P = .22 and P = .36) (Fig 4).
Discussion
This meta-analysis demonstrated that the pooled incidence 
rates of pulmonary embolism (PE) and deep vein thrombo-
sis (DVT) in patients with coronavirus disease 2019 (CO-
VID-19) were 16.5% and 14.8%, respectively, and substantial 
interstudy heterogeneity was present. The multivariable meta-
regression analysis demonstrated that greater disease severity 
and universal screening with CT pulmonary angiography were 
significantly associated with a higher incidence of PE (P , .001 
for both). Furthermore, 42.4% of patients with PE had DVT, 
and PE was more frequently located in the peripheral portion 
of the pulmonary arteries than in the central portion (60.4% 
vs 39.0%). D-dimer levels greater than 500 mg/L and greater 
than 1000 mg/L showed high sensitivity (96% and 91%, re-
spectively) but low specificity (10% and 24%, respectively) for 
the diagnosis of PE in patients with COVID-19.
Although PE has been reported to occur frequently in 
patients with COVID-19 and to be associated with a poor 
prognosis (27), its actual incidence is unknown. The reported 
incidence of PE ranged from 0.7% to 57.0% in the studies 
included in this meta-analysis. This variation in the reported 
incidence can be assumed to reflect differences across stud-
ies in the disease severity of the study population and the 
frequency of performing diagnostic imaging studies, such as 
CT pulmonary angiography. Accordingly, the multivariable 
meta-analysis revealed that greater disease severity and uni-
versal screening with CT pulmonary angiography were sig-
nificantly associated with a higher incidence of PE (P , .001 
for both).
In this meta-analysis, the pooled incidence of PE was 24.7% 
in patients admitted to the ICU, although it was high (10.5%) 
even in patients not admitted to the ICU. The PE incidence 
was higher than the reported value in patients with non–CO-
VID-19 viral pneumonia who were admitted to the ICU or 
who had acute respiratory distress syndrome (range, 1.3%–
7.5%) (25,33). Besides the increased risk of venous thrombo-
embolism in acutely ill patients, another hypothesis—in situ 
immunothrombosis—has been proposed to explain the high 
incidence of PE in patients with COVID-19 (39), as previous 
autopsy studies found multiple thrombi in small to medium 
pulmonary arteries (40–43). In a recent systematic review, 
microthrombosis was frequently observed in lung histopatho-
logic analysis of the population with COVID-19 (57%), which 
was higher than that in the population with H1N1 influenza 
(24%) (44). This hypothesis is supported by the results of a 
previous study, which reported that the PE phenotype in 
Pulmonary Embolism and Deep Vein Thrombosis in COVID-19
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Figure 3: Summary receiver operating characteristic curve shows 
the diagnostic performance of D-dimer tests for pulmonary embolism in 
patients with coronavirus disease 2019. Dots of different colors indicate 
separate data of 11 studies.
patients with COVID-19 was different from the PE pheno-
type in patients without COVID-19 pneumonia; specifically, 
in patients with COVID-19, the thrombotic lesions were more 
distributed in the peripheral arteries of the lung, and the total 
clot burden was lower (5). Similarly, the results of our meta-
analysis support the hypothesis that in situ thrombosis partly 
contributes to prothrombotic events in COVID-19 because 
DVT was present in only 42.4% of patients with PE, which 
was lower than the usual prevalence (60%) of DVT in patients 
with PE (45), and more than half of PEs were located in the 
distal pulmonary arteries.
Because most CT pulmonary angiographic examinations 
are performed based on clinical suspicion rather than system-
atic screening, the incidence of PE may be somewhat underesti-
mated, especially in cases of small segmental or subsegmental PE 
(27). Therefore, D-dimer levels play a crucial role in screening 
and the ultimate diagnosis of PE (14). The elevation of D-dimer 
levels in the COVID-19 population may stem from prothrom-
botic coagulopathy or pulmonary microvascular thrombosis be-
yond the resolution of CT pulmonary angiography.
Because D-dimer levels tend to be elevated even in patients 
with COVID-19 without PE, D-dimer cutoffs for PE screening 
can be a substantial concern in the care of patients with CO-
VID-19. In our study, the conventional cutoff values (500 or 
1000 mg/L) showed high sensitivity (96% and 91, respectively), 
which is comparable to the sensitivity of D-dimer levels in pa-
tients without COVID-19 (46). In fact, higher cutoff values than 
those conventionally used (.1000 mg/L) reduced the sensitivity, 
limiting the clinical application of D-dimer levels as a screening 
examination to rule out PE. Our results suggest that the con-
ventional cutoffs of D-dimer levels in preexisting guidelines can 
be applicable to the COVID-19 population for PE screening 
that serves as a basis for subsequent CT pulmonary angiographic 
examinations (46,47). However, considering the low diagnostic 
performance (area under the curve, 0.737) of D-dimer tests and 
the relatively lower negative predictive value in patients admitted 
to the ICU, a combination of pretest clinical probability assess-
ment and age-adjusted D-dimer cutoff values could improve the 
diagnostic yield of D-dimer levels (48,49).
In all but three of the included studies, patients received anti-
coagulation with a prophylactic or therapeutic dose. Generally, it 
Table 3: Meta-Regression of Incidence of PE
Parameter




OR P Value I2† OR P Value
Study design … .25 0.934 NA NA
 Retrospective (n = 20) 1 … … … …
 Prospective (n = 2) 1.7 [0.7, 4.5] … … … …
Study population … .02 0.927 … ,.001
 Non-ICU or various (n = 12) 1 … … 1 …
 ICU or critically ill patients (n = 18) 2.9 [1.6, 5.2] … … 3.5 [1.9, 6.3] …
Anticoagulation … .38 0.939 NA NA
 None or unknown (n = 2) 1 … … … …
 Yes (n = 20) 0.8 [0.4, 1.4] … … … …
Proportion of patients undergoing CT 
 pulmonary angiography
… .002 0.908 … ,.001
 Some patients or unknown (n = 15) 1 … … 1 …
 All patients (n = 7) 3.7 [1.7, 7.9] … … 5.1 [2.3, 11.5] …
Note.—Numbers in parentheses are 95% CIs. Variables with P , .2 at univariable analysis were included in the multivariable analysis. 
P , .05 was considered to indicate a significant difference in the multivariable analysis. ICU = intensive care unit, NA = not applicable, 
OR = odds ratio, PE = pulmonary embolism.
* I2 is 0.861 after multivariable metaregression analysis.
† Data indicate the percentage of residual heterogeneity among the unaccounted-for variances. 
Suh et al
Radiology: Volume 00: Number 0— 2020  n  radiology.rsna.org 9
Figure 4: Funnel plots used to detect publication bias. Each circle represents a study included in the analysis. Probability values of asymmetry from the Egger test are 
shown. (a) Incidence of pulmonary embolism (PE). (b) Incidence of deep vein thrombosis (DVT).
Table 4: Estimated Sensitivities, Specificities, and Predictive Values at Specific D-dimer Values
Cutoff (mg/L) Sensitivity (%) Specificity (%)
Non-ICU Patients* ICU Patients*
Negative Predictive  
Value (%)
Positive Predictive  
Value (%)
Negative Predictive  
Value (%)
Positive Predictive  
Value (%)
500 96 (93, 97) 10 (7, 14) 95 (89, 100) 11 (10, 12) 88 (78, 97) 26 (25, 27)
1000 91 (86, 94) 24 (18, 32) 96 (92, 99) 12 (11, 13) 89 (83, 94) 28 (27, 30)
2000 81 (72, 87) 48 (38, 59) 96 (93, 98) 15 (13, 18) 88 (85, 92) 34 (31, 37)
3000 72 [(61, 81) 63 (51, 73) 95 (93, 97) 19 (16, 22) 87 (84, 91) 39 (35, 43)
Note.—Data in parentheses are 95% CIs. The expected sensitivity, specificity, and positive and negative predictive values at specific D-
dimer values were estimated for patients admitted to the intensive care unit (ICU) and those not admitted to the ICU, with an assumption 
that the pooled incidence of pulmonary embolism in our study could reflect the actual prevalence.
* CIs for predictive values were estimated with a sample size of 500, an approximate number of patients with individual D-dimer data in 
this study.
is recommended that critically ill patients who require ICU care 
receive prophylactic anticoagulation because they are considered 
to be at high thrombotic risk as a result of extended periods of 
immobilization, mechanical ventilation, and vascular injury or 
surgery (50). In consideration of the high frequency of venous 
thromboembolism and the positive effect of heparin for reduc-
ing mortality in patients with COVID-19, systematic pharma-
cologic thromboprophylaxis is recommended for all patients 
who require hospital admission for COVID-19, even if they do 
not receive care in the ICU (51). However, the high incidence 
of PE or DVT despite prophylactic anticoagulation may sug-
gest that a more reinforced thromboprophylaxis regimen could 
reduce venous thromboembolism and improve the prognosis of 
patients with COVID-19 (22).
Our study had several limitations. First, a substantial propor-
tion (48%) of the included studies were of low quality, probably 
because they intended to promptly report the significance of PE in 
COVID-19, a rapidly spreading condition with substantial public 
health implications. Nevertheless, to our knowledge, our meta-
analysis was the largest one to investigate the incidence of PE and 
DVT in the COVID-19 population. Second, the incidence of PE 
and DVT reported herein could be an overestimate relative to the 
entire COVID-19 population, as the included studies preferen-
tially analyzed patients with severe disease and our literature search 
based on the search term thrombosis/embolism might have resulted 
in a low likelihood of including studies with zero incidence. Third, 
the effect of the dose or regimen of anticoagulation was not inves-
tigated because this information was often unavailable or insuf-
ficient in the included studies. Fourth, we analyzed baseline D-
dimer levels at admission, and changes in D-dimer levels could 
not be considered in the analysis. Fourth, the prognostic impact 
of PE was not assessed in this meta-analysis because we focused 
on the incidence of PE or DVT and the diagnostic accuracy and 
cutoff of D-dimer levels for PE diagnosis.
In conclusion, the pooled incidence rates of pulmonary em-
bolism (PE) and deep vein thrombosis (DVT) in patients with 
coronavirus disease 2019 (COVID-19) were high, at 16.5% and 
14.8%, respectively, and exceeded 20% in patients admitted to 
the intensive care unit. PE was confined to the peripheral pul-
monary arteries in more than half of patients with PE, and DVT 
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was found in less than half of the patients with PE. The D-dimer 
cutoffs used to exclude PE (500 and 1000 mg/L) in the preexist-
ing guidelines seem to be applicable to patients with COVID-19.
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